Prediction of Blood Pressure Outcomes Following Renal Denervation (PREDICT-RDN)

Launched by HEART CENTER LEIPZIG - UNIVERSITY HOSPITAL · Feb 20, 2025

Keywords

ClinConnect Summary

The PREDICT-RDN clinical trial is studying how a procedure called renal denervation can help people with uncontrolled high blood pressure, also known as hypertension. This trial aims to understand how this treatment affects daily blood pressure levels and the time spent in a healthy blood pressure range. Researchers will also create a model to predict how much blood pressure might decrease after the procedure.

To participate in this trial, individuals must be at least 18 years old and have high blood pressure that remains above 140/90 mmHg despite being treated with three to five different blood pressure medications. Participants can expect to have their blood pressure monitored closely after the renal denervation procedure. It’s important to know that certain conditions, like having a single functioning kidney or being pregnant, may prevent someone from joining the study. The trial is not currently recruiting participants but will be starting soon.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Confirmed arterial hypertension with systolic or diastolic blood pressure \>140/90 mmHg in standardized office blood pressure measurement
• • 2. Treatment with 3 to ≤5 antihypertensive drug classes
• • 3. Age \>18 years
• • 4. Written informed consent
• Exclusion Criteria:
• • 1. Age ≤ 18 years
• • 2. anatomy unsuitable for renal denervation (i.e. renal artery stenosis, single functioning kidney)
• • 3. pregnancy
• • 4. patients under legal supervision or guardianship
• • 5. participation in other trials that might interfere with the study outcome according to the opinion of one of the investigators.